Gland Pharma Ltd

Gland Pharma Ltd announced the conclusion of a routine USFDA Good Manufacturing Practice (GMP) Inspection at its Visakhapatnam facilities, specifically the VSEZ Sterile Oncology Formulations Facility and API Facility. The inspection, conducted between August 24, 2026, and September 01, 2026, resulted in zero Form 483 observations. This outcome is a positive indicator of the company's compliance with international regulatory standards, potentially bolstering investor confidence and ensuring continued market access for its products.

Gland Pharma Ltd has announced the appointment of Mr. Deepak Sapra as its new Chief Executive Officer (CEO), effective November 16, 2026. This decision was approved by the Board based on the recommendation of the Nomination and Remuneration Committee. Mr. Sapra brings extensive experience, with 27 years in executive roles, including over 23 years in the pharmaceutical industry. He currently serves as the CEO of API and Services at Dr. Reddy’s Laboratories Limited and is a Board Member of Aurigene Pharma Services. His background includes global portfolio strategy, B2B business leadership, revenue growth, market expansion, and M&A across various international markets. He holds degrees in Mechanical Engineering and Management, with further studies at the University of Bradford and Carnegie Mellon University.

Gland Pharma Limited announced its financial results for the first quarter ended June 30th, 2026, reporting record revenues of ₹18,003 million, a 20% increase year-on-year. Profit After Tax (PAT) surged by 47% year-on-year to ₹3,170 million. The company highlighted strong execution of its CDMO strategy and resilience in its B2B business model, with both segments contributing 50% of revenues and showing significant growth. CDMO revenue grew by 20% YoY, while B2B revenue increased by 19% YoY. Adjusted EBITDA also saw a substantial rise of 37% YoY to ₹5,102 million, with an improved margin of 28%. The company continues to invest in differentiated technologies and capacity expansions to support sustainable long-term growth.

Gland Pharma Limited announced that its Board of Directors, in a meeting held on August 10, 2026, has approved the Unaudited Financial Results (standalone and consolidated) for the quarter ended June 30, 2026. These results have been reviewed and recommended by the Audit Committee and prepared in compliance with Indian Accounting Standards (Ind AS). The company also submitted the Limited Review Report(s) and a press release with an investor presentation. The board meeting commenced at 15:00 IST and concluded at 16:05 IST.

Gland Pharma's consolidated PAT for Q1 FY27 (quarter ended June 30, 2026) came in at ₹316.96 Cr, up 47.1% YoY from ₹215.48 Cr, on consolidated revenue of ₹1,800.27 Cr, up 19.6% YoY from ₹1,505.62 Cr — both clean of one-off items in either period. Sequentially, revenue grew a modest 3.3% QoQ while PAT fell 13.6% QoQ from ₹366.68 Cr; that dip is fully explained by other income dropping to ₹61.2 Cr from ₹111.5 Cr in the seasonally front-loaded Q4, not by core operating weakness. Margins expanded across the board: EBITDA margin rose to 27% from 24% a year ago (Adj. EBITDA margin 28% vs 25%), and PAT margin widened roughly 330bps to ~17.6% from ~14.3% on a revenue-from-operations basis, per the company's own reconciliation. The expansion was broad-based — CDMO (50% of revenue) grew 20% YoY to ₹891.5 Cr and B2B (50%) grew 19% YoY to ₹908.8 Cr, so neither engine is carrying the other. The US led geographically with 32% YoY growth to ₹981 Cr, aided by four new US molecule launches this quarter (including Multi-Vitamin and Leucovorin calcium) and 3 ANDA filings/7 approvals, taking the cumulative US ANDA count to 389 (342 approved). Standalone PAT of ₹364.39 Cr running ahead of the ₹316.96 Cr consolidated figure reflects continued drag from the European Cenexi subsidiary, which management still targets toward mid-teen EBITDA margins. Our pre-result preview flagged Street consensus tracking a conservative 9% FY27 revenue growth target, 14 analysts (10 buy) with average price targets of ₹2,189-2,286 pricing the stock for 'on-plan' delivery, and an EBITDA margin heartbeat of 17-19% to watch — this quarter's 20% reported YoY growth and 27% EBITDA margin both clear that bar (the preview's separately-flagged ₹350-380 Cr 'on-plan Q1 revenue' figure looks mismatched against the ₹1,800 Cr actual scale and is disregarded here as unreliable). Against management's own FY27 guidance from the Q4 concall — 12-13% constant-currency revenue growth and 25-26% EBITDA margins — the quarter beats on both revenue pace and margin. Management's press-release framing, crediting 'successful execution of our CDMO strategy and the resilience of our B2B business model' driven by 'recent product launches from CDMO portfolio and strong customer demand,' is borne out by the numbers, with both CDMO and B2B growing in the high-teens/20% range. The quarter also coincided with a new CDMO deal with an unnamed global pharma major (~USD 90-100 Mn annualized revenue potential from CY29) and a sterile-API manufacturing tie-up with Neuland Laboratories, plus the August 25 AGM notice proposing a ₹20/share dividend. Going into Q2, the USFDA approval for Sugammadex (a $1.6 Bn US opportunity, approved July 29) landed too late in Q1 to show up in this print — its early uptake is the first real test. The other swing factor is whether the 20% YoY growth pace normalizes toward the 12-13% CC guidance range through the rest of FY27, or whether the CDMO pipeline and new launches keep it running ahead of guidance.

Gland Pharma Limited has announced a strategic Manufacturing and Supply Agreement (MSA) with a leading global pharmaceutical company. This partnership establishes Gland Pharma as an integrated, end-to-end CDMO partner for a portfolio of sterile injectable products, including oncology and non-oncology drugs in various presentations like vials, ampoules, and pre-filled syringes. The agreement covers technology transfer, process development, manufacturing, and long-term supply. It is expected to provide strong long-term business visibility, with revenue generation anticipated from calendar year 2029. The deal currently includes 55 SKUs across three sites, with potential for expansion, and an estimated annualized revenue potential of USD 90-100 million upon full commercialization. This collaboration marks a significant milestone for Gland Pharma's CDMO business growth.

Gland Pharma Limited and Neuland Laboratories Limited have announced a long-term strategic Contract Development and Manufacturing Organization (CDMO) partnership. This collaboration focuses on expanding sterile Active Pharmaceutical Ingredient (API) manufacturing capabilities, particularly for microparticle depot products. Gland Pharma will establish a new, cGMP-compliant sterile manufacturing suite at its Visakhapatnam facility, adding approximately 1400 kg of annual capacity. The partnership aims to leverage Neuland's complex API development expertise with Gland Pharma's sterile manufacturing and regulatory track record to meet growing global demand and enhance supply chain resilience.

Gland Pharma Ltd. is dispatching letters to shareholders who have not registered their email addresses, providing a weblink and QR code to access the Notice of the 48th Annual General Meeting (AGM) and the Annual Report for FY 2025-26. The 48th AGM is scheduled for Tuesday, August 25, 2026, at 11:00 A.M. (IST) via Video Conferencing/Other Audio Visual Means. The company also reminds shareholders to update their KYC details and dematerialize physical securities as per SEBI regulations. This includes updating PAN, address, mobile number, bank account details, specimen signature, and nomination choice for physical holders. Payments like dividends will only be electronic from April 1, 2024, for non-compliant folios. Shareholders are encouraged to register email IDs for online services and to support green initiatives.

Gland Pharma Ltd has announced its 48th Annual General Meeting (AGM) scheduled for Tuesday, August 25, 2026, to be held via video conference. The company will present the audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026. A key agenda item is the declaration of a final dividend of ₹20 per equity share for FY 2025-26. E-voting will be open from August 22 to August 24, 2026, with a cut-off date of August 18, 2026, for eligibility.

Gland Pharma Ltd. has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, fulfilling the requirements of Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The BRSR is integrated into the company's Annual Report for FY2025-26 and is accessible on its website. All disclosures within the report are presented on a standalone basis and have received a reasonable level of assurance from DNV Business Assurance India Private Limited. The company's core business, pharmaceutical research, development, manufacturing, and marketing of complex injectables, constitutes 100% of its turnover.